Opportunity | Market Size Estimate | India's Position | Key Companies Positioned |
GLP-1 Peptide Intermediates (Ozempic, Wegovy, Mounjaro class) | Global GLP-1 drug market >$100B by 2030. Peptide intermediate market multi-$B | Divi's (Kakinada), Laurus Labs, Aurobindo (Kakinada fermentation). Amino acid building blocks — both solid and liquid phase synthesis | Divi's Laboratories, Laurus Labs, Aurobindo, Piramal |
Contrast Media APIs (Iopamidol, Iohexol, Iopromide, Gadolinium) | ~$3B global market. Supply disrupted post-COVID. High barriers to entry | Divi's already commercial in Iopamidol, Iohexol, and Iopromide. Gadolinium in qualification. iodine chemistry deep expertise | Divi's Laboratories (dominant), Jubilant |
HPAPI (High Potency APIs — oncology, cytotoxics, ADCs) | Global HPAPI market ~$35B by 2030 at 8%+ CAGR | India has specialised containment suites (OEL <1 µg/m³). Divi's Kakinada, Piramal, Cipla, Dishman. China is underdeveloped in containment | Divi's, Piramal, Dishman, Cipla |
CDMO / Custom Synthesis for Big Pharma | India CDMO market: $20B in 2023, projected $44B by 2030 (~₹3,69,600 Cr) | China+1 strategy creating 50% RFQ spike since Q3 2024. India has a 10-year advantage in chemistry talent and regulatory depth | Divi's, Laurus, Aurobindo, Divis, Syngene, Piramal |
Biosimilars API | Global biosimilar market $35-40B by 2030. Adalimumab, bevacizumab, trastuzumab generics | Samsung Biologics (Korea) leads. India: Dr. Reddy's, Biocon, Intas building biological API capacity | Dr. Reddy's, Biocon, Intas, Zydus |
ARV / Anti-Infective APIs for Global Health Markets | PEPFAR, Global Fund orders growing. Africa/LatAm demand for affordable HIV, TB, malaria APIs | India supplies 90%+ of global ARV API volume. WHO prequalified list dominance. | Laurus Labs, Aurobindo, Mylan (Viatris), Cipla |
Fermentation-Based Antibiotic self-sufficiency under PLI | ₹6,940 Cr scheme targeting Penicillin-G, 7-ACA, Erythromycin, Rifampicin domestically | Three parks + PLI incentives. 38 molecules now produced. Import savings expected ₹10,000+ Cr by 2029 | Aurobindo (Kakinada 6-APA), CSPC, Orchid Pharma |